The Effect of Food on the Pharmacokinetics of a BI 425809 Tablet Formulation Administered as a Single Dose With and Without Food to Healthy Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Trial)
Latest Information Update: 05 Jan 2023
At a glance
- Drugs Iclepertin (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 02 Jan 2023 Status changed from active, no longer recruiting to completed.
- 06 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2022 Status changed from not yet recruiting to recruiting.